Mavalon Therapeutics
Hatfield
About Mavalon Therapeutics
Mavalon Therapeutics is a company focused on stopping the progression of Parkinson’s disease. The biotechnology company is developing mGluR3 allosteric modulators for the treatment of Parkinson's disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $9.9M
- Funding stage: Seed
- Last round: Seed (Oct 2016)
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/mavalon-therapeutics-113470 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.